Vidyya Medical News Service
*
Volume 5 Issue 152 Published - 14:00 UTC 08:00 EST 1-June-2003 Next Update - 14:00 UTC 08:00 EST 2-June-May-2003
little clear gif used for spacer
.
*

Study shows age does not affect response to prostate cancer treatment: Chemotherapy is as effective in the elderly as it in younger patients
There is no difference in efficacy or in the toxicity effects of weekly docetaxel (Taxotere) treatment between men aged 70 or older and those younger than 70 who have prostate cancer, according to a study conducted by Oregon Health & Science University scientists. The study was presented on May 31, 2003, at the American Society of Clinical Oncology's annual meeting in Chicago, Illinois.  more

*
Analysis of long-term response population from Bexxar clinical trials presented at ASCO
According to data presented yesterday at the 39th annual meeting of the American Society of Clinical Oncology (ASCO, Abstract #2316), a high proportion of patients with advanced low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) who achieved long-term, durable responses to Bexxar(R) (tositumomab and iodine I 131 tositumomab) therapy had complete responses and many of these patients remain in remission five or more years after treatment (median 59.1 months, range 47.2-NR). Bexxar therapy, being co-developed by Corixa Corporation, is an investigational radioimmunotherapy in the final stages of regulatory review by the U.S. Food and Drug Administration (FDA). more

 


*
Data provide further reassurance of favorable risk/benefit for Arimidex (anastrozole) over Tamoxifen
The role of 'Arimidex' (anastrozole) as an alternative treatment option to tamoxifen in postmenopausal women with early breast cancer was reinforced by further data presented yesterday. Important safety data from the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial show, that over a five year safety follow-up, the difference in the risk of bone fracture between anastrozole and tamoxifen stabilises after two years of treatment and does not continue to increase.  more

*
An EORTC study shows irinotecan enhances standard chemotherapy, increasing progression-free survival by 35 percent in colorectal cancer patients
The addition of irinotecan (also known as CPT-11) to a regimen of 5-fluorouracil/leucovorin (5-FU/LV) significantly increased the median progression free survival in metastatic colorectal cancer patients by nearly 35 percent, according to Phase III results from a large, multicenter study funded by an educational grant conducted by the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group. Investigators announced the new findings yesterday at the 39th American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 1018, poster discussion on Saturday, May 31 between 1:30 PM and 5:30 PM CT, location S106). more

*
Mature survival data confirms Faslodex (fulvestrant) as an effective treatment choice in advanced breast cancer
Results presented for the first time yesterday at the American Society of Clinical Oncology (ASCO) annual meeting(1), show that postmenopausal women with advanced breast cancer treated with the novel estrogen receptor downregulator, 'Faslodex' (fulvestrant), have comparable survival to women treated with 'Arimidex' (anastrozole) - an established therapy in advanced breast cancer.  more

 
little clear gif used for a space